24. James Cox, Las Cruces, New Mexico, Court of Federal Claims No: 13–0238V.
25. Chanel and Paul A. Monroe on behalf of Angelina Monroe, Las Vegas, Nevada, Court of Federal Claims No: 13–0239V.
27. Tamika M. Kratzer on behalf of Ian M. Kratzer, Sacramento, California, Court of Federal Claims No: 13–0243V.
28. Rosalie Peck, Boston, Massachusetts, Court of Federal Claims No: 13–0249V.
29. Shannon Keller, Sacramento, California, Court of Federal Claims No: 13–0250V.
30. Edwina Bradshaw, North Myrtle Beach, North Carolina, Court of Federal Claims No: 13–0252V.
31. William and Brenda Lehann Rodriguez on behalf of C.R., Clayton, Georgia, Court of Federal Claims No: 13–0253V.
32. Corrine K. Ibane, Kamuela, Hawaii, Court of Federal Claims No: 13–0257V.
33. Lorel Cabuno, San Juan, Puerto Rico, Court of Federal Claims No: 13–0259V.
34. Brittany and Davey Lambert on behalf of Noah Lambert, Memphis, Tennessee, Court of Federal Claims No: 13–0265V.
35. Scott and Caroline VanScy on behalf of Alyssa VanScy, Simi Valley, California, Court of Federal Claims No: 13–0266V.
37. Georgia Murdock, Silver Spring, Maryland, Court of Federal Claims No: 13–0273V.
38. Willie Andre Simmons, Augusta, Georgia, Court of Federal Claims No: 13–0274V.
40. Allison and Steven Council on behalf of Adam Council, Plainfield, Illinois, Court of Federal Claims No: 13–0276V.
41. Maryann Giordano, Lindenhurst, New York, Court of Federal Claims No: 13–0277V.
42. Laura A. Jones, Greensboro, North Carolina, Court of Federal Claims No: 13–0279V.
43. David D. Griffin, Afghanistan, Court of Federal Claims No: 13–0280V.
44. James Demoski, Endicott, New York, Court of Federal Claims No: 13–0286V.
45. Christina N. Steinat, Seattle, Washington, Court of Federal Claims No: 13–0287V.
46. Jessica L. Stone, Baraboo, Wisconsin, Court of Federal Claims No: 13–0289V.
47. Holly Rhew, Wichita, Kansas, Court of Federal Claims No: 13–0293V.
48. Janet DeYear, Dallas, Texas, Court of Federal Claims No: 13–0299V.
49. Cynthia Adkins, Sarasota, Florida, Court of Federal Claims No: 13–0295V.
50. Saurabh V. and Archana Amin on behalf of Sheea Amin, Linwood, New Jersey, Court of Federal Claims No: 13–0300V.
51. Juliet and Mohamed Eddo on behalf of Justin Eddo, Miami, Florida, Court of Federal Claims No: 13–0302V.
52. James Boyer, Boston, Massachusetts, Court of Federal Claims No: 13–0303V.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Ryan White HIV/AIDS Program, Part C Early Intervention Services Grant Under the Ryan White HIV/AIDS Program

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice of Ryan White HIV/AIDS Program Part C Early Intervention Services One-Time Noncompetitive Award to Ensure Continued HIV Primary Medical Care.

SUMMARY: To prevent a lapse in comprehensive primary care services for persons living with HIV/AIDS, HRSA will provide a one-time noncompetitive Ryan White HIV/AIDS Program Part C funds award to the Genesis Health Group (GHG), Davenport, Iowa.

SUPPLEMENTARY INFORMATION: The amount of the award to ensure ongoing HIV medical services is $429,112.

Authority: Section 2651 of the Public Health Service Act, 42 U.S.C. 300ff–51CFDA Number: 93.918

Project period: The period of support for this award is 15 months, explained below in further detail.

Justification for the Exception to Competition: The Community Health Care, Davenport, Iowa (Grant Number: H76HA00212) announced the relinquishment of their Part C grant on January 31, 2013. To prevent a lapse in HIV medical care, grant funds of $429,112 are to be awarded to GHG to provide interim HIV medical care. The $429,112 represents a proportional share of the last award to the Community Health Care to cover 15 months of HIV medical primary care services until the service area is competed for by July 1, 2014.

FOR FURTHER INFORMATION CONTACT: John Fanning, Public Health Analyst, Division of Community Based Programs/Southern Branch, HRSA, by mail at 5600 Fishers Lane, Rockville, MD 20857; by email at jfanning@hrsa.gov; or by phone at (301) 443–0493.

Dated: May 17, 2013.

Mary K. Wakefield, Administrator.

[FR Doc. 2013–12347 Filed 5–23–13; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; 60-day Comment Request: Autism Spectrum Disorder Research Portfolio Analysis

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Institute of Mental Health (NIMH), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) The quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

To Submit Comments and For Further Information: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request
more information on the proposed project, contact: The Office of Autism Research Coordination, NIMH, NIH, Neuroscience Center, 6001 Executive Blvd., MSC 9633, Room 6184, Bethesda, MD 20892 or Email your request, including your address to: iaccpublicinquries@mail.nih.gov.

Formal requests for additional plans and instruments must be requested in writing.

Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.


Need and Use of Information Collection: The purpose of the ASD portfolio analysis is to collect research funding data from U.S. and international ASD research funders, to assist the Interagency Autism Coordinating Committee (IACC) in fulfilling the requirements of the Combating Autism Act, and to inform the committee and interested stakeholders of the funding landscape and current directions for ASD research. Specifically, these analyses will examine the extent to which current funding and research topics align with the IACC Strategic Plan for ASD Research. The findings will help guide future funding priorities by outlining current gaps and opportunities in ASD research as well as serving to highlight annual activities and research progress.

OMB approval is requested for three years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 419.

**ESTIMATED ANNUALIZED BURDEN HOURS**

<table>
<thead>
<tr>
<th>Type of respondents (funders)</th>
<th>Number of respondents</th>
<th>Number of response per respondent</th>
<th>Average Time per Response (in hours)</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. Federal</td>
<td>26</td>
<td>36</td>
<td>15/60</td>
<td>234</td>
</tr>
<tr>
<td>U.S. Private</td>
<td>12</td>
<td>54</td>
<td>15/60</td>
<td>162</td>
</tr>
<tr>
<td>International Government</td>
<td>4</td>
<td>14</td>
<td>15/60</td>
<td>14</td>
</tr>
<tr>
<td>International Private</td>
<td>4</td>
<td>9</td>
<td>15/60</td>
<td>9</td>
</tr>
</tbody>
</table>

Dated: March 26, 2013.

Sue Murrin,
Executive Officer, NIMH, NIH.

[FR Doc. 2013–12420 Filed 5–23–13; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications/contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel, AIDS and Cancer Specimen Resource (ACSR)
**Date:** May 29, 2013
**Time:** 12:00 p.m. to 5:00 p.m.
**Agenda:** To review and evaluate grant applications

**Place:** National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 1E030, Rockville, MD 20850 (Telephone Conference Call)

**Contact Person:** Donald L Coppack, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, Shady Grove—NIMH, 9609 Medical Center Drive, Room 7W260, Bethesda, MD 20892, 240–276–6382, donald.coppack@nih.gov

This notice is being published less than 15 days prior to the meeting date due to scheduling conflicts.

**Name of Committee:** National Cancer Institute Special Emphasis Panel, NCI Program Project Meeting II
**Date:** June 12–13, 2013
**Time:** 8:00 a.m. to 5:00 p.m.
**Agenda:** To review and evaluate grant applications

**Place:** Hilton, Rockville, 1750 Rockville Pike, Rockville, MD 20852

**Contact Person:** Majed M. Hamawy, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division Of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W120, Bethesda, MD 20892, 240–276–6457, mh101v@mail.nih.gov

**Name of Committee:** National Cancer Institute Special Emphasis Panel, Innovative Technologies for Cancer Biospecimen Science
**Date:** June 12, 2013
**Time:** 12:00 p.m. to 5:00 p.m.
**Agenda:** To review and evaluate grant applications

**Place:** National Cancer Institute—Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 1E030, Rockville, MD 20850 (Telephone Conference Call)

**Contact Person:** Donald L Coppack, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W260, Bethesda, MD 20892, 240–276–6382, donald.coppack@nih.gov

**Name of Committee:** National Cancer Institute Special Emphasis Panel, RNA Biosensors
**Date:** June 13, 2013
**Time:** 1:00 p.m. to 3:00 p.m.
**Agenda:** To review and evaluate contract proposals

**Place:** National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 6W034, Rockville, MD 20850 (Telephone Conference Call)

**Contact Person:** Bratim K. Saha, Ph.D., Scientific Review Officer, Program Coordination and Referral Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W556, Bethesda, MD 20892, 240–276–6411, suhab@mail.nih.gov

**Name of Committee:** National Cancer Institute Special Emphasis Panel, R13 Review Teleconference
**Date:** June 25, 2013
**Time:** 1:00 p.m. to 5:00 p.m.
**Agenda:** To review and evaluate grant applications

**Place:** National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 6W034, Rockville, MD 20850 (Telephone Conference Call)

**Contact Person:** Bratim K. Saha, Ph.D., Scientific Review Officer, Program Coordination and Referral Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W556, Bethesda, MD 20892, 240–276–6411, suhab@mail.nih.gov

**Name of Committee:** National Cancer Institute Special Emphasis Panel, NCI Omnibus Biology
**Date:** July 15–16, 2013

**Place:** National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 1E030, Rockville, MD 20850 (Telephone Conference Call)

**Contact Person:** Donald L Coppack, Ph.D., Scientific Review Officer, Special Review